Berman Capital Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Berman Capital Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$17K	Sell	136 -62	-31%	-$9.37K	﹤0.01%	1034
2021 Q2	$35K	Buy	198 +160	+421%	+$27.7K	0.01%	715
2021 Q1	$6K	Hold	38	–	–	﹤0.01%	1214
2020 Q4	$6K	Buy	38 +1	+3%	+$149	﹤0.01%	1091
2020 Q3	$5K	Buy	37 +5	+16%	+$620	﹤0.01%	1044
2020 Q2	$3K	Sell	32 -22	-41%	-$2.43K	﹤0.01%	1147
2020 Q1	$5K	Buy	54 +1	+2%	+$129	﹤0.01%	889
2019 Q4	$7K	Hold	53	–	–	﹤0.01%	879
2019 Q3	$6K	Sell	53 -6	-10%	-$804	﹤0.01%	896
2019 Q2	$8K	Buy	59 +6	+11%	+$806	﹤0.01%	812
2019 Q1	$7K	Buy	+53	New	+$6.91K	﹤0.01%	770

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Berman Capital Advisors's JAZZ Position: Q3 2021 in Review

Berman Capital Advisors reduced its Jazz Pharmaceuticals (JAZZ) stake by 31% in Q3 2021, selling an estimated $9.37K and leaving 136 shares worth $17K. The position accounts for ﹤0.01% of the portfolio, ranked #1034.

Berman Capital Advisors first reported a position in JAZZ in Q1 2019 and has held it in 11 quarters since. The position peaked at $35K in Q2 2021. 455 funds tracked by Wall St. Rank hold JAZZ as of Q3 2021.

Berman Capital Advisors held 136 shares of Jazz Pharmaceuticals worth $17K as of Q3 2021.
Berman Capital Advisors sold 62 Jazz Pharmaceuticals shares in Q3 2021, an estimated $9.37K.
Jazz Pharmaceuticals made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #1034 holding.
Berman Capital Advisors first reported a position in Jazz Pharmaceuticals in Q1 2019 and has held it in 11 quarters since.
Berman Capital Advisors's Jazz Pharmaceuticals position peaked at $35K in Q2 2021.
455 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.